Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents.

Although an apparent trend toward decreased rates of treatment failure was noted for those receiving initial antifungal combination therapy, the all-cause 1-year mortality was not statistically different between AmB versus combination AmB + POS or ISA group (68% vs 57%).

also in 709 other papers